Key stats
About ICBC CREDIT SUISSE
Home page
Inception date
Mar 26, 2025
Structure
Open-Ended Fund
China Securities Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Gross
Replication method
Physical
Dividend treatment
Distributes
Primary advisor
ICBC Credit Suisse Fund Management Ltd.
ISIN
CNE100006VP6
Classification
Returns
| 1 month | 3 months | Year to date | 1 year | 3 years | 5 years | |
|---|---|---|---|---|---|---|
| Price performance | — | — | — | — | — | — |
| NAV total return | — | — | — | — | — | — |
Dividends
Dividend payout history
Assets under management (AUM)
Fund Flows
Frequently Asked Questions
159217 assets under management is 4.12 B CNY. It's risen 50.17% over the last month.
159217 fund flows account for 2.39 B CNY (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
No, 159217 doesn't pay dividends to its holders.
159217 shares are issued by ICBC Credit Suisse Asset Management Co., Ltd. under the brand ICBC. The ETF was launched on Mar 26, 2025, and its management style is Passive.
159217 follows the China Securities Hong Kong Stock Connect Innovative Drug Index - CNY - Benchmark TR Gross. ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
159217 trades at a premium (0.31%) meaning the ETF is trading at a higher price than the calculated NAV.